Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

Abstract: Described herein are systems and methods for implementing a look up table by a network node, and performing or supporting time synchronization based on the look up table. In one aspect, a network node may receive a packet. The network node can identify a few number of bits in the packet, and determine one or more actions or functions corresponding to the few number of bits via the look up table. In addition, the network node can execute or perform the determined one or more actions to support time synchronization.

Abstract: Described herein are systems and methods for implementing a look up table by a network node, and performing or supporting time synchronization based on the look up table. In one aspect, a network node may receive a packet. The network node can identify a few number of bits in the packet, and determine one or more actions or functions corresponding to the few number of bits via the look up table. In addition, the network node can execute or perform the determined one or more actions to support time synchronization.

Abstract: The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.

Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

Abstract: Disclosed are optical devices suitable as security devices for document authentication, which comprise at least one two-dimensional array of elongate laser-modified tracks extending within a document substrate that have a distinct optical refractive index compared to the unmodified substrate, which can exhibit excellent diffractive effects. Also disclosed are the use of such devices for document authentication and methods for their production.

Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

Abstract: Described herein are systems and methods for implementing a look up table by a network node, and performing or supporting time synchronization based on the look up table. In one aspect, a network node may receive a packet. The network node can identify a few number of bits in the packet, and determine one or more actions or functions corresponding to the few number of bits via the look up table. In addition, the network node can execute or perform the determined one or more actions to support time synchronization.

Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

Abstract: Disclosed are optical devices suitable as security devices for document authentication, which comprise at least one two-dimensional array of elongate laser-modified tracks extending within a document substrate that have a distinct optical refractive index compared to the unmodified substrate, which can exhibit excellent diffractive effects. Also disclosed are the use of such devices for document authentication and methods for their production.

Abstract: Systems, apparatuses, and methods for reducing latency when consuming an encoded video bitstream in real-time are disclosed. A video encoder encodes a video bitstream and writes chunks of the encoded bitstream to a bitstream buffer. Prior to the encoder completing the encoding of an entire frame, or an entire slice of a frame, a consumer module consumes encoded chunks of the bitstream. In one implementation, to enable pipelining of the consumption with the encoding, the encoder updates a buffer write pointer with an indication of the amount of data that has been written to the bitstream buffer. The consumer module retrieves encoded data from the bitstream buffer up to the location indicated by the buffer write pointer. In this way, the consumer module is able to access and consume encoded video data prior to the encoder finishing encoding an entire frame or an entire slice of the frame.

Abstract: Systems, apparatuses, and methods for reducing latency when consuming an encoded video bitstream in real-time are disclosed. A video encoder encodes a video bitstream and writes chunks of the encoded bitstream to a bitstream buffer. Prior to the encoder completing the encoding of an entire frame, or an entire slice of a frame, a consumer module consumes encoded chunks of the bitstream. In one implementation, to enable pipelining of the consumption with the encoding, the encoder updates a buffer write pointer with an indication of the amount of data that has been written to the bitstream buffer. The consumer module retrieves encoded data from the bitstream buffer up to the location indicated by the buffer write pointer. In this way, the consumer module is able to access and consume encoded video data prior to the encoder finishing encoding an entire frame or an entire slice of the frame.

Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

Abstract: Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

Abstract: A compound having the structure: